EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

J Randolph Hecht iD, Julian R Molina iD, Kirstin Liechty, Theodore H Welling, Patrick M Grierson, Sandip P Patel, Kedar Kirtane iD, M Pia Morelli, Frederick L Locke, David G Maloney, Salman R Punekar, Sarah Nikiforow und 12 weitere

BMJ Oncology · 2026-01 · 5 (1) · e001033

DOI: 10.1136/bmjonc-2025-001033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMJ Oncology, online erschienen am 27.03.2026. Verfasst von J Randolph Hecht und 23 weiteren Autor:innen. Beteiligte Einrichtung: UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: A2 Biotherapeutics Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Identifying eligible patients for precision oncology clinical trials is challenging, particularly for rare molecular subpopulations. To address this challenge, A2 Biotherapeutics developed BASECAMP-1 ( NCT04981119 ), a non-interventional master screening study to identify patients eligible for interventional studies of logic-gated Tmod chimeric antigen receptor T-cell therapies. Eligible patients for these interventional trials have an advanced solid malignancy and are germline human leucocyte antigen (HLA)-A*02 heterozygous, with tumour-associated HLA-A loss of heterozygosity (LOH). HLA-A LOH occurs in ~16% of advanced solid malignancies; therefore, an efficient screening strategy is required. This report describes BASECAMP-1; compares the efficiency of two screening methods; and discusses the broader advantages of BASECAMP-1 beyond efficient enrolment. Methods and analysis Patients are identified for BASECAMP-1 using two approaches. In the traditional approach, common for clinical trials, investigators consent and screen all patients who might be good candidates for cell therapy trials, with no prior knowledge of patient HLA-A type or LOH status. To further optimise our approach, we co-developed with Tempus AI (Tempus) the bioinformatic programme Aware, which identifies potentially eligible patients with tumour-associated HLA-A*02 LOH within a clinico-genomic database that includes linked genomic and transcriptomic sequencing and clinical data collected during routine care.

Results

Over 42 months of using a traditional approach to identify eligible patients, 1918 patients at 13 study sites were consented and screened for BASECAMP-1; of these, 30 patients with tumour-associated HLA-A*02 LOH were enrolled (~0.7 participants per month). Over the last 30 months of that same period, Tempus Aware screening was implemented and 55 patients with tumour-associated HLA-A*02 LOH were enrolled (~1.8 participants per month). The bioinformatic approach identified more patients than the traditional approach and used sequencing results produced as part of the standard clinical tumour sequencing workflow, reducing resource use and study staff burden. Additional advantages of using a screening study, such as BASECAMP-1, include manufacturing efficiencies and collection of a large dataset of molecular and clinical parameters that can be used to supplement trial analyses.

Conclusions

The BASECAMP-1 study demonstrates a clinico-genomic screening approach can more efficiently identify patients for precision oncology trials. Furthermore, precision oncology can be enhanced through collaborative data-sharing. Trial registration number NCT04981119 .

Schlagwörter

Stichwörter der Autor:innen

Cell therapyClinical TrialMetastatic cancerSolid tumour

Autor:innen und Institutionen

  • UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • A2 Biotherapeutics Inc, Agoura Hills, California, USA.
  • UCSD Moores Cancer Center, San Diego, California, USA.
  • Washington University in St Louis, St. Louis, Missouri, USA.
  • Moffitt Cancer Center, Tampa, Florida, USA.

ORCID-Profile: J Randolph Hecht, Julian R Molina, Kedar Kirtane, Jessica C Tebbets

Förderung

  • A2 Biotherapeutics Inc.

Zitieren

APA

Hecht, J. R., Molina, J. R., Liechty, K., Welling, T. H., Grierson, P. M., Patel, S. P., Kirtane, K., Morelli, M. P., Locke, F. L., Maloney, D. G., Punekar, S. R., Nikiforow, S., Lin, Y., Ulrickson, M., Specht, J. M., Lozac'hmeur, A., Osterman, C. K., Garde, R. J., Rangel, G. A., …, & Simeone, D. M. (2026). BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials. BMJ Oncology, 5(1), e001033. https://doi.org/10.1136/bmjonc-2025-001033

Vancouver

Hecht JR, Molina JR, Liechty K, Welling TH, Grierson PM, Patel SP, et al. BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials. BMJ Oncology. 2026;5(1):e001033. doi:10.1136/bmjonc-2025-001033

BibTeX
@article{Hecht2026,
  author = {Hecht, J Randolph and Molina, Julian R and Liechty, Kirstin and Welling, Theodore H and Grierson, Patrick M and Patel, Sandip P and Kirtane, Kedar and Morelli, M Pia and Locke, Frederick L and Maloney, David G and Punekar, Salman R and Nikiforow, Sarah and Lin, Yi and Ulrickson, Matthew and Specht, Jennifer M and Lozac'hmeur, Ariane and Osterman, Chelsea K and Garde, Ryan J and Rangel, Gena A and Ng, Eric W and Welch, John S and Tebbets, Jessica C and Go, William Y and Simeone, Diane M},
  title = {BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials},
  journal = {BMJ Oncology},
  year = {2026},
  volume = {5},
  number = {1},
  pages = {e001033},
  doi = {10.1136/bmjonc-2025-001033}
}
Kostenlos starten →